Theravance Biopharma, Inc. $TBPH Stake Decreased by Oasis Management Co Ltd.

Oasis Management Co Ltd. cut its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 35.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 727,161 shares of the biopharmaceutical company’s stock after selling 391,774 shares during the quarter. Theravance Biopharma accounts for 0.9% of Oasis Management Co Ltd.’s portfolio, making the stock its 10th biggest holding. Oasis Management Co Ltd. owned 1.44% of Theravance Biopharma worth $13,605,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of TBPH. AQR Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $101,000. Jane Street Group LLC boosted its stake in shares of Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after buying an additional 88,540 shares in the last quarter. Creative Planning purchased a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $139,000. American Century Companies Inc. boosted its stake in shares of Theravance Biopharma by 6.8% in the second quarter. American Century Companies Inc. now owns 91,501 shares of the biopharmaceutical company’s stock valued at $1,009,000 after buying an additional 5,794 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Theravance Biopharma by 12.4% during the second quarter. Invesco Ltd. now owns 25,324 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 2,789 shares in the last quarter. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Up 0.9%

Shares of NASDAQ:TBPH opened at $16.64 on Friday. Theravance Biopharma, Inc. has a 52-week low of $10.42 and a 52-week high of $21.03. The stock’s fifty day simple moving average is $16.46 and its 200-day simple moving average is $17.47. The company has a market capitalization of $857.79 million, a P/E ratio of 7.56 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million during the quarter. On average, sell-side analysts anticipate that Theravance Biopharma, Inc. will post 1.58 earnings per share for the current year.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the sale, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.65% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TBPH. HC Wainwright boosted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 8th. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Finally, TD Cowen boosted their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.